A therapeutic vaccine for treating individuals who are carriers of a disease or pathogen that does not affect the brain, such as leishmaniasis, cancer or any pathogenic infection, comprises at least one cationic nanoparticle comprising a cationic polysaccharide core and a specific antigen, wherein the antigen is specific to the pathogen or disease.

Provided herein are imidazopyrimidine compounds for use in enhancing human immune response and/or as adjuvants in vaccines.

Provided herein are imidazopyrimidine compounds for use in enhancing human immune response and/or as adjuvants in vaccines.

Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.

Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.

The invention provides methods of tolerizing or treating a subject suffering from an autoimmune or autoinflammatory disease or disorder to an antigen associated with the autoimmune disease or disorder. The invention also features kits for carrying out the methods of the invention.

The invention provides methods of tolerizing or treating a subject suffering from an autoimmune or autoinflammatory disease or disorder to an antigen associated with the autoimmune disease or disorder. The invention also features kits for carrying out the methods of the invention.

The invention provides methods of tolerizing or treating a subject suffering from an autoimmune or autoinflammatory disease or disorder to an antigen associated with the autoimmune disease or disorder. The invention also features kits for carrying out the methods of the invention.

A vaccine composition for treating and preventing infection by protozoans is disclosed. The vaccine composition comprises carbohydrates and/or peptides present on the surface of the protozoan, optionally bound to an immunogenic protein nanoparticle.

A vaccine composition for treating and preventing infection by protozoans is disclosed. The vaccine composition comprises carbohydrates and/or peptides present on the surface of the protozoan, optionally bound to an immunogenic protein nanoparticle.